Format

Send to

Choose Destination
Curr Top Behav Neurosci. 2009;1:347-71. doi: 10.1007/978-3-540-88955-7_14.

Role of endocannabinoid signaling in anxiety and depression.

Author information

1
Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Abstract

Cannabinoid receptors and their endogenous ligands are located throughout the limbic, or "emotional," brain, where they modulate synaptic neurotransmission. Converging preclinical and clinical data suggest a role for endogenous cannabinoid signaling in the modulation of anxiety and depression. Augmentation of endocannabinoid signaling (ECS) has anxiolytic effects, whereas blockade or genetic deletion of CB₁ receptors has anxiogenic properties. Augmentation of ECS also appears to have anti-depressant actions, and in some assays blockade and genetic deletion of CB₁ receptors produces depressive phenotypes. These data provide evidence that ECS serves in an anxiolytic, and possibly anti-depressant, role. These data suggest novel approaches to treatment of affective disorders which could include enhancement of endogenous cannabinoid signaling, and warrant cautious use of CB₁ receptor antagonists in patients with pre-existing affective disorders.

PMID:
21104391
PMCID:
PMC3808114
DOI:
10.1007/978-3-540-88955-7_14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center